Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.45 |
| ▸ | MAOB | P27338 | 7/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173756 | 0.80 | MAPT (0.39) | CYP19A1MAOBAKR1B1 | |
| SCHEMBL2659525 | 0.77 | ESR1 (0.41) | CYP19A1MAOB | |
| SCHEMBL12275818 | 0.72 | PTGDR2 (0.32) | MAOB | |
| SCHEMBL8470357 | 0.71 | CYP19A1 (0.52) | CYP19A1MAOBAKR1B1LTB4RLTB4R2 | |
| SCHEMBL12275817 | 0.71 | ACHE (0.31) | MAOB | |
| SCHEMBL2172568 | 0.71 | CYP19A1 (0.46) | CYP19A1AKR1B1 | |
| SCHEMBL8473045 | 0.70 | CYP19A1 (0.41) | CYP19A1MAOBLTB4RLTB4R2 | |
| SCHEMBL915090 | 0.70 | MAOB (0.38) | MAOB | |
| SCHEMBL10897784 | 0.69 | GRM7 (0.47) | CYP19A1AKR1B1LTB4RLTB4R2 | |
| SCHEMBL12276942 | 0.69 | ACHE (0.34) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | CYP19A1 4216/4885MAOB 3253/4885AKR1B1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.